Teriflunomide
Aubagio
Pyrimidine Synthesis Inhibitor
NADAC/unit
$0.5439
No Shortage
Tier 1: 20.1%
PA Req: 63.8%
13 Manufacturers
26 ANDAs
indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
vs. brand Aubagio: Generic saves up to 95% per unit
Market Intelligence
2025-04-16 Class II Recall: Glenmark Pharmaceuticals Inc., USA
Generic Manufacturers
ACCORD HEALTHCARE INCALEMBIC PHARMACEUTICALS LTDAUROBINDO PHARMA LTDBIOCON PHARMA LTDCONCORD BIOTECH LTDGLENMARK SPECIALTY SAHETERO LABS LTD UNIT VMSN LABORATORIES PRIVATE LTDNATCO PHARMA LTDSANDOZ INCSANOFI AVENTIS US LLCSOLA PHARMACEUTICALSTEVA PHARMACEUTICALS USA INCZYDUS PHARMACEUTICALS USA INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.